Cart summary

You have no items in your shopping cart.

PCI-29732

SKU: orb1225284

Description

A selective and irreversible Btk inhibitor with biochemical Ki of 8.2 nM; also inhibits Lck and Lyn with Ki of 4.6 and 2.5 nM.(In Vitro):PCI29732 shows cytotoxicity in different cells. The IC50 values are 7.94 μM for S1, 7.79 μM for S1-MI-80, 6.55 μM for H460, 6.34 μM for H460/MX20, 6.14 μM for KB, 6.02 μM for KBv200, 12.45 μM for HEK293/pcDNA3, 14.58 μM for HEK293-ABCG2-482-R2, and 13.24 μM for HEK293-ABCG2-482-T7 cells.PCI-29732 blocks the transcriptional up-regulation of a panel of B-cell activation genes in human CD20+ B cells stimulated at the B-cell antigen receptor (BCR).(In Vivo):PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 and enhances the anti-tumor efficacy of substrate chemotherapeutic agents.PCI 29732 (20 mg/kg; p.o.; every 3 d × 5 times) enhances the anticancer efficacy of Topotecan in the H460/MX20 cell xenograft nude mice model.

Images & Validation

Key Properties

CAS Number330786-25-9
MW371.435
Purity>98% (HPLC)
FormulaC22H21N5O
SMILESNC1=C2C(N(C3CCCC3)N=C2C4=CC=C(OC5=CC=CC=C5)C=C4)=NC=N1
TargetBTK
SolubilityDMSO: ≥ 53 mg/mL

Bioactivity

In Vivo
PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 and enhances the anti-tumor efficacy of substrate chemotherapeutic agents. PCI 29732 (20 mg/kg; p.o. ; every 3 d × 5 times) enhances the anticancer efficacy of Topotecan in the H460/MX20 cell xenograft nude mice model. Animal model: 5-6 weeks old athymic nude mice (bearing H460/MX20 cells). Dosage: 20 mg/kg (combination with Topotecan; every 3 d × 5 times, i.p. , 3 mg/kg; topotecan was given 1 h after PCI29732 administration). Administration: p.o. ; every 3 d × 5 times. Result: Significant reductions in tumor weight and volume were observed in the group treated with PCI29732 in combination with Topotecan.
In Vitro
PCI29732 shows cytotoxicity in different cells. The IC50 values are 7.94 μM for S1, 7.79 μM for S1-MI-80, 6.55 μM for H460, 6.34 μM for H460/MX20, 6.14 μM for KB, 6.02 μM for KBv200, 12.45 μM for HEK293/pcDNA3, 14.58 μM for HEK293-ABCG2-482-R2, and 13.24 μM for HEK293-ABCG2-482-T7 cells. PCI-29732 blocks the transcriptional up-regulation of a panel of B-cell activation genes in human CD20+ B cells stimulated at the B-cell antigen receptor (BCR).

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

PCI29732 | PCI 29732

Similar Products

  • PCI 29732 [orb1302940]

    99.81%

    330786-25-9

    371.43

    C22H21N5O

    1 mg, 25 mg, 50 mg, 100 mg, 10 mg, 5 mg, 1 ml x 10 mM (in DMSO)
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

PCI-29732 (orb1225284)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

200 mg
500 mg
2 mg
$ 90.00
5 mg
$ 130.00
10 mg
$ 180.00
25 mg
$ 330.00
50 mg
$ 550.00
100 mg
$ 800.00